NCT06613100 - Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

September 19, 2026

Study Completion Date

January 23, 2030

Conditions

Prostate Cancer

Interventions

DRUG

Xaluritamig

Intravenous (IV) infusion

Trial Locations (7)

RECRUITING

Thomas Jefferson University, Philadelphia

RECRUITING

Universitaetsklinikum Hamburg Eppendorf, Hamburg

RECRUITING

The Ohio State University, Columbus

RECRUITING

Universitaetsklinikum Essen, Essen

RECRUITING

Medical College of Wisconsin, Milwaukee

RECRUITING

Washington University, St Louis

RECRUITING

University of California San Francisco, San Francisco